GlaxoSmithKline Pharmaceuticals: Q1CY13 Result Update
DSIJ Intelligence / 08 May 2013
GlaxoSmithKline Pharmaceuticals has posted muted results for the quarter ending March 31, 2013. The company reported a topline of Rs 632.14 crore as against Rs 622.78 crore for the previous fiscal same period, marking a growth of a mere 1.50%.
GlaxoSmithKline Pharmaceuticals has posted muted results for the quarter ending March 31, 2013. In Q1CY13, the company reported a topline of Rs 632.14 crore as against Rs 622.78 crore for the same period previous fiscal, marking a growth of a mere 1.50%.
On the margins front, its EBITDA for Q1CY13 stood at Rs 167.62 crore as against Rs 173.17 crore for Q1CY12 witnessing a fall of 3.20%. This translates into a decline in the EBITDA margin of 129 basis points to 26.52%. However, at the same time, its net profit witnessed growth of 37.40% on a YoY basis to stand at Rs 169.01 crore in Q1CY13 as against Rs 122.89 crore in Q1CY12.
The stock price of GlaxoSmithKline Pharmaceuticals rallied by more than 6% in yesterday’s trade. But the results have been a dampener as the stock closed yesterday with a gain of 2.63% only. On the valuation front, the stock trades at a PE of 34.97x, which is much higher as compared to other listed peers. The stock may witness some selling in today’s trade.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.